Erenumab (Aimovig) vs Ubrogepant (Ubrelvy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: CGRP receptor · full Migraine pipeline

Erenumab (Aimovig)

Marketed by Amgen and partners

Approved in Migrainemonoclonal antibody
Reliable signal

NCT02456740 · Phase 3 · completed

The trial randomly assigned 955 participants to erenumab 70 mg, erenumab 140 mg, or placebo and used quadruple blinding during the 24-week placebo-controlled phase. The clinical primary endpoint, change in monthly migraine days, was significantly better with both erenumab doses than with placebo.

Next expected readout: July 2031 · NCT07655440 (registry estimate)

Reported efficacy

Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) (met)

Result source: NCT03867201

Ubrogepant (Ubrelvy)

Marketed by AbbVie

Approved in Migrainesmall molecule
Reliable signal

NCT02828020 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial with 1,672 participants. Both ubrogepant doses met both primary clinical endpoints, with statistically significant improvements over placebo in pain freedom and relief of the most bothersome migraine-associated symptom at 2 hours.

Next expected readout: May 2027 · NCT05125302 (registry estimate)

Reported efficacy

Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants (met)

Result source: NCT04492020

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Erenumab (Aimovig)
Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase): Placebo -1.83 migraine days / month (Standard Error 0.18) | Erenumab 70 mg QM -3.23 migraine days / month (Standard Error 0.18) | Erenumab 140 mg QM -3.67 migraine days / month (Standard Error 0.18) NCT02456740 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly migraine days (last 4 of 12 weeks): erenumab 70 mg -6.64 and 140 mg -6.63 vs placebo -4.18; differences -2.46 (95% CI -3.52 to -1.39) and -2.45 (95% CI -3.51 to -1.38), both p<0.001 (CT.gov posted results). NCT02066415 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result
Change From Baseline in Monthly Migraine Days at Week 12 (4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase): Placebo -1.84 migraine days / month (Standard Error 0.21) | Erenumab 70 mg QM -2.88 migraine days / month (Standard Error 0.21) NCT02483585 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) NCT03867201 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Ubrogepant (Ubrelvy)
Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants NCT04492020 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Erenumab (Aimovig)'s landscape · Ubrogepant (Ubrelvy)'s landscape